Kiniksa Pharmaceuticals, Ltd , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
infoKiniksa Pharmaceuticals is a small cap stock with a total market cap of 1.27B.
infoThey trade on the NASDAQ and had their IPO 5 years and 2 months ago.
infoKiniksa Pharmaceuticals currently employs 220 people.
infoAs of Wednesday, Aug 23 2023, Kiniksa Pharmaceuticals’s share price is $18.04.
News Relating to Kiniksa Pharmaceuticals
Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
Tuesday Jul 25 2023 at 10:07
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16.
Seeking Alpha
Kiniksa Pharmaceuticals: Autoimmune Therapy Offers Attractive Prospects At Current Price
Wednesday Jul 19 2023 at 15:25
Innovations in the drug lineup, including ARCALYST, KPL-404, and Mavrilimumab, showcase Kiniksa’s dedication to targeting challenging autoimmune and inflammatory conditions. ARCALYST’s net product revenue in Q1 2023 summed to $42.7 million, with a full-year 2023 net product revenue estimate for ARCALYST ranging between $200 million and $215 million. Kiniksa is also evaluating KPL-404 for its potential in rheumatoid arthritis treatment, with Phase 2 clinical trial results anticipated in early 2024.
GlobeNewsWire
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
Monday Jul 17 2023 at 08:00
HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.
GlobeNewsWire
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
Saturday Jul 15 2023 at 02:00
HAMILTON, Bermuda, July 18, 2023 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.
InvestorPlace
3 Small-Cap Stocks That Are Worth the Gamble
Tuesday Jul 04 2023 at 20:24
While your friendly financial advisor probably won’t direct you to this space, small-cap stock picks can be worth your while, so long as you understand the volatility risks and don’t unreasonably stretch yourself. To set definitions, small-cap investments refer to companies which feature a market capitalization between $250 million to $2 billion.
Seeking Alpha
Kiniksa Pharmaceuticals: A Somewhat Complicated Story
Friday Jun 09 2023 at 12:32
Today, we take our first look at a commercial stage biopharma concern called Kiniksa Pharmaceuticals, Ltd. The company is seeing impressive growth from its primary drug asset and has an intriguing pipeline. An investment analysis follows in the paragraphs below.
GlobeNewsWire
Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
Tuesday Jun 06 2023 at 16:01
HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time).
Seeking Alpha
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2023 Earnings Call Transcript
Saturday May 06 2023 at 12:32
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank – Head of Investor Relations Sanj Patel – Chief Executive Officer Ross Moat – Chief Commercial Officer Mark Ragosa – Chief Financial Officer John Paolini – Chief Medical Officer Conference Call Participants Paul Choi – Goldman Sachs Geoff Meacham – Bank of America Operator Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Earnings Conference Call.
GlobeNewsWire
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
Monday May 01 2023 at 16:01
HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first quarter 2023 financial results and recent portfolio execution.
InvestorPlace
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Wednesday Apr 05 2023 at 13:40
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve’s possible response.
InvestorPlace
7 Small-Cap Stocks to Buy for Explosive Growth Potential
Thursday Mar 30 2023 at 14:20
While most financial advisors will direct you to a healthy portion of established, large-capitalization enterprises, small-cap stocks to buy provide extra oomph for willing participants. For example, age can be a determining factor in whether smaller, more speculative enterprises are appropriate.
InvestorPlace
7 Dirt-Cheap Stocks Sitting in the Sweet Spot
Thursday Mar 23 2023 at 14:25
While it’s always nice to get a discount, with cheap stocks, it may be better to go for enterprises sitting in the sweet spot; that is, publicly traded securities that are cheap but not too cheap where investors might fret about possible value traps. On this list, I’m only going to target (as of the time of writing) equity shares that trade between $10 and $20.
InvestorPlace
The Top 7 Growth Stocks in Biotech
Friday Mar 03 2023 at 18:57
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates
Tuesday Feb 28 2023 at 12:48
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022.
GlobeNewsWire
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
Monday Feb 27 2023 at 16:01
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.
Seeking Alpha
Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting
Sunday Feb 19 2023 at 08:28
Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors.
GlobeNewsWire
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Tuesday Jan 03 2023 at 16:01
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
GlobeNewsWire
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
Wednesday Nov 30 2022 at 16:01
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time.
GlobeNewsWire
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
Wednesday Nov 23 2022 at 16:01
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.
Zacks Investment Research
Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?
Thursday Nov 10 2022 at 11:17
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.
Zacks Investment Research
Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here’s Why
Monday Nov 07 2022 at 11:37
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
Seeking Alpha
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript
Tuesday Nov 01 2022 at 14:45
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.
GlobeNewsWire
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
Monday Oct 31 2022 at 16:01
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at 8:30 a.m. Eastern Time to report its third quarter 2022 financial results and corporate activities.
Zacks Investment Research
What Makes Kiniksa Pharmaceuticals, Ltd. (KNSA) a Good Fit for “Trend Investing”
Wednesday Oct 05 2022 at 10:32
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here’s Why
Wednesday Sep 21 2022 at 13:33
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects.
Zacks Investment Research
Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 106% to Reach the Level Wall Street Analysts Expect?
Monday Aug 22 2022 at 11:17
The consensus price target hints at a 106% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Seeking Alpha
Kiniksa Pharmaceuticals, Ltd. (KNSA) CEO Sanj Patel on Q2 2022 Results – Earnings Call Transcript
Friday Aug 05 2022 at 15:45
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Rachel Frank – Head of Investor Relations Sanj Patel – Chief Executive Officer Eben Tessari – Chief Operating Officer Mark Ragosa – Chief Financial Officer Ross Moat – Chief Commercial Officer Conference Call Participants Jason Zemansky – Bank of America Anupam Rama – JPMorgan Operator Good morning and welcome to the Kiniksa Pharmaceuticals Second Quarter 2022 Financial Earnings Conference Call.
Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates
Wednesday Aug 03 2022 at 09:47
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022.
Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here’s What You Should Know
Friday Jul 22 2022 at 14:04
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects.
Seeking Alpha
Kiniksa Pharmaceuticals (KNSA) CEO Sanj Patel on Q1 2022 Results – Earnings Call Transcript
Saturday May 07 2022 at 16:12
Kiniksa Pharmaceuticals (NASDAQ:KNSA ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Rachel Frank – Head of IR Sanj Patel – CEO and Chairman Ross Moat – Chief Commercial officer Mark Ragosa – CFO John Paolini – Chief Medical Officer Eben Tessari – COO Conference Call Participants Anupam Rama – JPMorgan. Paul Choi – Goldman Sachs David Nierengarten – Wedbush Securities Alexandria Hammond – Geoff Meacham Liisa Bayko – Evercore ISI Operator Good day, and thank you for standing by.
Kiniksa Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Kiniksa Pharmaceuticals’s Altman Z-score is 10.72 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Kiniksa Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $555.16K of common stock in Kiniksa Pharmaceuticals on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Kiniksa Pharmaceuticals’s Income Quality of 0.2 is lower than its Industry Group of 0.69 (-71.0% lower)
Kiniksa Pharmaceuticals’s Income Quality of 0.2 is lower than its Major Industry Group of 0.71 (-71.8% lower)
Kiniksa Pharmaceuticals’s Income Quality of 0.2 is lower than its Sector of 0.75 (-73.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Kiniksa Pharmaceuticals’s Current Ratio of 3.9 is lower than its Industry Group of 4.76 (-18.1% lower)
Kiniksa Pharmaceuticals’s Current Ratio of 3.9 is in line with its Major Industry Group of 4.32 (-9.7% lower)
Kiniksa Pharmaceuticals’s Current Ratio of 3.9 is greater than its Sector of 2.6 (50.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (5.47 & -1.27)
Cannot compare a negative PE Ratio (5.47 & -1.1)
Cannot compare a negative PE Ratio (5.47 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compare a negative PB Ratio (-2.59 & 1.34)
Cannot compare a negative PB Ratio (-2.59 & 1.4)
Cannot compare a negative PB Ratio (-2.59 & 1.62)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Kiniksa Pharmaceuticals’s ROE of -0.47 is in line with its Industry Group of -0.44 (-6.8% lower)
Kiniksa Pharmaceuticals’s ROE of -0.47 is lower than its Major Industry Group of -0.38 (-23.7% lower)
Kiniksa Pharmaceuticals’s ROE of -0.47 is lower than its Sector of -0.03 (-1466.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Kiniksa Pharmaceuticals’s ROCE of -0.08 is greater than its Industry Group of -0.42 (81.0% greater)
Kiniksa Pharmaceuticals’s ROCE of -0.08 is greater than its Major Industry Group of -0.37 (78.4% greater)
Kiniksa Pharmaceuticals’s ROCE of -0.08 is lower than its Sector of -0.04 (-100.0% lower)
Derived from SEC.GOV filing dataopen_in_new